Eptinezumab
- Generic Name
- Eptinezumab
- Brand Names
- Vyepti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1644539-04-7
- Unique Ingredient Identifier
- 8202AY8I7H
- Background
Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.
- Indication
Eptinezumab is indicated for the preventive treatment of migraine in adults.
- Associated Conditions
- Migraine
- Associated Therapies
- -
Efficacy of Vyepti highlighted by new clinical trial results in severe migraine
New RESOLUTION trial results show Vyepti® (eptinezumab) significantly reduces monthly migraine days (MMDs) in patients with chronic migraine and medication-overuse headache, with rapid benefits observed.
H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial of Vyepti
H. Lundbeck A/S announced Vyepti® (eptinezumab) met primary and secondary endpoints in SUNRISE trial, reducing monthly migraine days significantly compared to placebo. Lundbeck plans to discuss with regulatory authorities to make Vyepti available in Asia. Safety profile was similar to placebo, with COVID-19 and nasopharyngitis as most common adverse events.
Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti
Lundbeck's Vyepti® (eptinezumab) met primary and secondary endpoints in phase III SUNRISE trial, showing significant reductions in monthly migraine days and early preventive effects, with plans to discuss regulatory approval for Asian markets.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath